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Abstract
Introduction The origin and clinical relevance of circulating cell-
free tumor DNA in the blood of cancer patients is still unclear.
Here we investigated whether the detection of this DNA is
related to bone marrow (BM) micrometastasis and tumor
recurrence in breast cancer patients.
Methods BM aspirates of 81 primary breast cancer patients
were analyzed for the presence of disseminated tumor cells
(DTC) by immunocytochemistry using the pan-cytokeratin
antibody A45-B/B3. PCR-based fluorescence microsatellite
analysis was performed for detection of loss of heterozygosity
(LOH) at 6 polymorphic markers using cell-free serum DNA. The
data were correlated with established risk factors, and patients
were followed-up over 6-10 years.
Results LOH was detected in 33.5% of blood samples. The
occurrence of LOH at the entire microsatellite marker set
correlated with histopathology (P = 0.05) and grading (P =
0.006) of the primary tumor. The genomic region characterized
by marker D9S171 was only affected by LOH in patients with
increased tumor stages (pT2-4, P < 0.05) and older age (≥ 55
years, P = 0.05). Kaplan-Meier analysis showed that LOH at
D3S1255 (P  = 0.009) and D9S171 (P  = 0.001) were
significantly associated with tumor relapse. In BM, DTC were
detected in 39.5% of the patients, and this finding correlated
with distant metastases (P < 0.05). Patients with DTC-positive
BM had higher DNA yields in their blood than patients with DTC-
negative BM (P < 0.05). However, no significant correlations
were found between the presence of DTC in BM and the
detection of marker-specific LOH on blood DNA.
Conclusions The detection of LOH on cell-free tumor DNA in
blood is unrelated to BM micrometastasis and provides
independent information on breast cancer progression.
Introduction
Early hematogenous dissemination of tumor cells is a common
phenomenon in breast cancer, which escapes detection by
common staging procedures and limits the improvement of
breast cancer mortality rates. In this regard, the spread of dis-
seminated tumor cells (DTC) into the bone marrow (BM) is
recorded in up to 40% of breast cancer patients at primary
diagnosis, and their presence is being considered as an inde-
pendent prognostic factor for reduced survival, as demon-
strated by a pooled analysis of more than 4700 breast cancer
patients [1]. Furthermore, DTC have been shown to persist in
BM after conventional adjuvant chemotherapy (even after
high-dose chemotherapy), and this persistence was associ-
ated with a worse prognosis [1-7]. Nevertheless, the detection
of minimal residual disease (MRD) needs to be improved by
additional factors because many BM-negative patients still
relapse [4].
One of these factors might be cell-free DNA which is dis-
charged during tumorigenesis from apoptotic and necrotic
BM: bone marrow; CEA: carcino embryonal antigen; CI: confidence interval; CK+: cytokeratin-positive; CTC: circulating tumor cells; DTC: dissemi-
nated tumor cells; ER: estrogen receptor; LOH: loss of heterozygosity; Mab: monoclonal antibody; MRD: minimal residual disease; PBS: phosphate-
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cells of the primary tumor into peripheral blood of patients with
diverse tumor entities, including breast cancer [8-10]. Also, an
active release of DNA by intact cells has been discussed [11].
Our recent study on cell-free DNA in blood from prostate can-
cer patients suggested that this DNA may also be originate
from micrometastatic lesions [12]. This finding provided the
rationale for the current study, which evaluates whether the
detection of tumor-specific DNA in the blood of breast cancer
patients is related to the presence of BM micrometastasis.
As BM aspirations are less accepted by patients than taking
blood samples, the analyses of genetic alterations in blood
from tumor patients might become a particularly attractive
approach to assess MRD. For the detection of tumor-specific
DNA in blood, the PCR-based microsatellite analysis is a com-
monly used and specific assay. By this method allelic imbal-
ance of tumor suppressor genes, for example loss of
heterozygosity (LOH), can be easily and rapidly determined
[13]. The occurrence of LOH, leading to loss of the paired
gene product, has been implicated in tumor development, pro-
gression and metastases [14]. Our findings have shown that
LOH at particular chromosomal loci may reflect tumor cell
spread in breast cancer patients [15]. Although a number of
studies have evaluated the potential of circulating tumor-asso-
ciated DNA in blood for the molecular diagnosis and progno-
sis of various types of cancer [9], the prognostic value of cell-
free DNA to identify breast cancer patients at high risk for
relapse is largely unknown.
Therefore, the purpose of this study was to study the prognos-
tic relevance of LOH on cell-free DNA at six breast cancer-rel-
evant chromosomal loci in the blood of patients with newly
diagnosed breast cancer and to evaluate whether this DNA is
a marker of MRD using the presence of DTC in BM as a well-
established MRD indicator.
Materials and methods
Characterization of study patients and healthy 
volunteers
The present study was conducted at the Department of
Obstetrics and Gynecology at the University Hospital in
Essen. In total, 81 patients with primary breast cancer were
studied from April 1998 until January 2003. Additionally, 10
healthy female controls aged between 30 and 50 years and
with no history of cancer were recruited. Overall survival data
of these patients were obtained from the local municipal reg-
istry; the median follow-up time was 6.2 years (range 0.2 to
9.8 years). Informed written consent was obtained from all
patients, and the study was approved by the Local Essen
Research Ethics Committee (05/2856). The clinical data of
the patients are summarized in Table 1.
The median age of the patients was 56 years (range 33 to 81
years). All four initial tumor stages were included, with a pre-
dominance of stage I and II. Most patients had ductal breast
Table 1
Patient characteristics at the time of primary diagnosis of 
breast cancer
Patients (%) LOH (%)§ DTC (%)$
Total 81 27 (33.5) 32 (39.5)
Age 56 years (range 33-81) 24 (41)
Family history 4 (31)
negative 58 (73) 21 (36) 4 (50)
positive 13 (17) 5 (39)
unknown 8 (10) 1 (13) 28 (37)
Patient subgroup
M0 76 (94) 27 (36)
M1 5 (6) 0 (0) 4 (80)
Tumor size
pT1 33 (41) 14 (42) 11 (33)
pT2 39 (48) 12 (31) 17 (44)
pT3-4 9 (11) 1 (11) 4 (44)
Nodal status
pN0 49 (62) 19 (39) 21 (43)
pN1-2 30 (38) 8 (27) 10 (33)
Histology
Ductal 60 (75) 23 (38) 20 (33)
Lobular 10 (12.5) 3 (30) 6 (60)
Others* 10 (12.5) 1 (10) 6 (60)
Grading
I-II 51 (65) 23 (45) 21 (41)
III 28 (35) 4 (14) 10 (36)
ER status
negative 23 (28.5) 6 (26) 9 (39)
positive 58 (71.5) 21 (36) 23 (40)
PR status
negative 29 (36) 8 (28) 8 (28)
positive 52 (64) 19 (37) 24 (46)
CEA
negative 69 (86) 25 (36) 27 (39)
positive 11 (14) 2 (18) 5 (46)
CA15-3
negative 67 (84) 25 (37) 27 (40)
positive 13 (16) 2 (15) 5 (39)
Therapy
BCT 45 (56) 20 (44) 14 (31)
Ablation 36 (44) 7 (22) 18 (50)
*n = 5 tumors were characterized as mixed ductal/lobular 
carcinomas of the breast; in five tumors histology was unknown. 
Among these five tumors were three cases of inflammatory breast 
cancer and one case of a carcinoma sarcoma of the breast with 
unknown histological subtype.
§total loss of heterozygosity (LOH) detected at all six markers in 
blood
$ disseminated tumor cells (DTC) detected in bone marrow
BCT = breast conserving therapy; CEA = carcino embryonal 
antigen; ER = estrogen receptor; PR = progesterone receptor.Available online http://breast-cancer-research.com/content/11/5/R71
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cancer and 49 women were node negative. High and moder-
ately differentiated tumors were predominant. Two-thirds of
the tumors were estrogen receptor (ER) negative and proges-
terone receptor (PR) positive, respectively. All patients under-
going breast-conserving therapy received an adjuvant
radiation. Patients with hormone receptor-positive tumors
received an adjuvant hormonal treatment with tamoxifen or an
aromatase inhibitor. The chemotherapeutic adjuvant treatment
mostly contained anthracyclines and taxanes.
Immunohistochemical analysis
For each of the 81 patients, the tumor type, TNM-staging and
grading were assessed according to the World Health Organ-
ization-classification of tumors of the breast [16] and the sixth
edition of the TNM Classification System [17]. The ER and PR
receptor status were determined by immunohistochemistry.
Determination of serum tumor markers
For the quantitative determination of carcino embryonal anti-
gen (CEA)/CA15-3 in human serum and plasma, 10 ml serum
were collected and assessed using the Elecsys CEA/CA15-3
immunoassays (Roche, Mannheim, Germany). The serial
measurement of CEA/CA15-3 was intended to aid in the man-
agement of cancer patients. These assays were performed on
a Cobas® immunoassay analyzer in the central laboratory of
University Hospital in Essen according to the manufacturer's
instruction. The central laboratory has a valid certification for
the performance of these assays following international guide-
lines.
Preparation of bone marrow
BM cells were isolated from heparinized BM (5000 U/ml BM)
by Ficoll-Hypaque density gradient centrifugation (density
1.077 g/mol; Pharmacia, Freiburg, Germany) at 400 g for 30
minutes. Interface cells were washed (400 g for 15 minutes)
and resuspended in PBS. For the detection of cytokeratin-
positive (CK+) cells, 3 × 106 cells (1 × 106 per slide and area
of 240 mm2) from each aspiration side were directly spun
(400 g for 5 minutes) onto glass slides coated with poly-L-
lysine (Sigma, Deisenhofen, Germany) using a Hettich cyto-
centrifuge (Tuttlingen, Germany).
Immunocytochemistry
After overnight air drying, staining of CK+ cells was performed
using the Epimet® kit (Micromet, Munich, Germany). The iden-
tification of epithelial cells using this kit is based on the reac-
tivity of the murine monoclonal antibody (Mab) A45-B/B3,
directed against a common epitope of CK polypeptides. The
kit uses Fab fragments of the pan-Mab conjugated with alka-
line phosphatase molecules. The method includes: permeabi-
lization of the cells by a detergent (5 minutes); fixation by a
formaldehyde-based solution (10 minutes); binding of the con-
jugate Mab A45-B/B3-alkaline phosphatase to cytoskeletal
CKs (45 minutes); and formation of an insoluble red reaction
product at the binding site of the specific conjugate (15 min-
utes). Subsequently, the cells were counterstained with
Mayer's hematoxylin for one minute and finally mounted with
Kaiser's glyzerine/gelatine (Merck, Darmstadt, Germany) in
Tris-EDTA buffer (Sigma, Deisenhofen, Germany). A conju-
gate of Fab-fragment served as a negative control. For each
test a positive control slide with the breast carcinoma cell line
MCF-7 (ATTC, Rockville, MD, USA) was treated under the
same conditions. The microscopic evaluation was carried out
independently by two investigators. Patients were evaluated
as tumor cell-positive if at least one CK-positive cell was
detected as analyzed by immunocytochemistry.
Preparation of serum and leukocytes
From each patient, 10 ml whole blood was collected in routine
S-Monovette®  tubes (Sarstedt AG&Co, Nümbrecht, Ger-
many) and immediately stored at 4°C. Serum and leukocyte
preparations were performed within four hours. The blood
samples were centrifuged at 2500 g for 10 minutes. The
upper phase contained the blood serum, from which 3 to 4 ml
was removed for the extraction and analysis of the circulating
DNA. The remaining 16 to 17 ml blood was supplemented up
to 50 ml with lysis buffer containing 0.3 M sucrose, 10 mM
Tris-HCl pH 7.5, 5 mM MgCl2 and 1% Triton X100 (Sigma,
Taufkirchen, Germany). Following incubation for 15 minutes
on ice, the isolation and purification of the leukocytes were
carried out by two centrifugation steps at 2500 g, 4°C for 20
minutes.
Preparation of paraffin-embedded tumor tissue
Tumor tissue of 22 patients was available. Specimens were
retrieved from the Institute of Pathology and Neuropathology
of the University Hospital of Essen. Tumor pieces of 3 mm in
size were processed from paraffin-embedded tumor blocks
and embedded in paraffin again to perform six sections of 10
to 20 μm thickness. The sections were dewaxed in 1 ml xylene
on a shaker incubator at 45°C for five minutes. After centrifu-
gation at full speed and room temperature for five minutes, the
supernatant was removed. Pellets were washed in 1 ml of eth-
anol and centrifuged at full speed for five minutes. The super-
natant was removed, and the pellet was dried at 45°C for two
to five minutes until the ethanol had evaporated.
DNA extraction and fluorescence-labeled PCR
For the PCR-based fluorescence microsatellite analyses we
used our former microsatellite method without extended frac-
tionation step [15], because the fractionation technique which
separates blood DNA in short and long DNA fragments was
not yet established [18] when blood samples were collected
between 1998 and 2003.
Genomic DNA was extracted from tumor tissues, leukocytes
and serum of peripheral blood using the QIAamp Blood DNA
Mini Kit (Qiagen, Hilden, Germany) according to the manufac-
turer's instructions. Quantification and quality of the extracted
DNA were determined spectrophotometrically using the Bio-Breast Cancer Research    Vol 11 No 5    Schwarzenbach et al.
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Photometer (Eppendorf, Hamburg, Germany) or the Nano-
Drop Spectrometer ND-1000 (Peqlab Biotechnologie,
Erlangen, Germany). To determine the lowest portion of tumor-
specific DNA which can be flawlessly detected, dilution exper-
iments were performed. For this study we mixed and amplified
known quantities and proportions of normal leukocyte and
serum DNA, as described before [18].
Serum, tumor and leukocyte (reference) DNA were amplified
with a PCR using primer pairs binding to microsatellite mark-
ers as summarized in Table 2. PCR conditions were described
before [15]. To confirm the microsatellite alterations, each
PCR was repeated at least twice.
Evaluation of PCR products
The fluorescence-labeled PCR products were separated by
capillary gel electrophoresis and detected on an automated
Genetic Analyzer 310 (Applied Biosystems, Freiburg, Ger-
many). Fragment length and fluorescence intensity were eval-
uated by the GeneScan software. The 500-ROX size marker
(Applied Biosystems, Freiburg, Germany) served as an inter-
nal standard. The LOH incidence was determined by calculat-
ing the ratio of the intensities of the two alleles from a serum
or tumor sample corrected by the ratio of the intensities of the
two alleles from the corresponding leukocyte sample which
served as reference DNA. LOH was interpreted if the final quo-
tient was less than 0.6 or more than 1.67. Homozygous and
non-analyzable peaks were designated as non-informative
cases.
Statistical analysis
The statistical analyses were performed using the SPSS soft-
ware package, version 13.0 (SPSS Inc. Chicago, IL, USA).
The chi-square or two-tailed Fischer's exact test, and the uni-
variate binary logistical regression were used to identify possi-
ble associations between the occurrence of DTC in BM, DNA
concentrations and LOH patterns in blood and the following
established risk factors of the patients with primary breast can-
cer: age, histology results, tumor stage (TNM), nuclear grade,
ER and PR status, presence of tumor markers CEA and CA15-
3, relapse time, menopause status, family history, and use of
chemotherapy, radiotherapy and hormone therapy. In addition,
the Mann and Whitney-U and the Wilcoxon-W test for the non-
parametric comparison of two independent and dependent
variables were used, respectively. Kaplan-Meier plots were
drawn on to estimate overall survival and recurrence, and the
log rank test was used for statistical analyses. A P value of less
than 0.05 was considered as statistically significant.
Results
Clinical relevance of cell-free DNA concentrations
DNA was extracted from blood serum of 81 breast cancer
patients. The range of DNA concentrations was between 58
and 5317 ng/ml of serum with a mean value of 886 ng/ml and
a median value of 519 ng/ml. As shown in the box plot of Fig-
ure 1a, the patients with lobular breast cancer had significantly
higher DNA levels in their blood than patients with ductal
breast cancer (P < 0.03, Table 3). Patients with DTC-positive
BM had higher DNA yields than patients with DTC-negative
BM (P < 0.05, Figure 1b).
Furthermore, the comparison of the DNA levels in the blood of
the tumor patients with those of 10 healthy controls showed
that minor DNA yields circulate in blood of healthy individuals.
This background level of normal DNA probably results from
apoptotic lymphocytes present in the blood sample [13,15].
The range of DNA concentrations of the control group was
between 36 and 156 ng/ml of serum with a mean value of 60
ng/ml and a median value of 45 ng/ml (data not shown).
LOH frequency in tumor samples
A PCR-based fluorescence microsatellite analysis was per-
formed using a panel of six different polymorphic microsatellite
markers (Table 2). Tumor tissue specimens of 22 patients
were available and served as positive controls. The matched
leukocyte DNA (normal DNA) of each patient served as a ref-
Table 2
Microsatellite markers used for loss of heterozygosity analysis
Microsatellite
markers
Chromosomal
region
Tumor suppressor gene Function
D3S1255 3p24.2-25 unknown
D9S171 9p21 P16 (INK4A) Regulator of cell cycle
D10S1765 10q23.3 PTEN
phosphatase and tensin homologue
Regulator of cell growth, metabolism and survival
D13S218 13q12-13 BRCA2
Breast cancer type 2
Regulator of cell cycle
D16S421 16q22-23 E-cadherin Epithelial cell adhesion molecule
D17S855 17q21 BRCA1
Breast cancer type 2
Regulator of cell cycleAvailable online http://breast-cancer-research.com/content/11/5/R71
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erence sample. LOH was found in every second tumor tissue
(50%). Of the 11 patients, 4 patients showed 1 LOH in their
tumor sample, 4 patients showed 2, 1 patient showed 3 and 2
patients showed 4 LOH in their tumor sample (data not
shown). The overall LOH incidence in the specimens of all
analyzed microsatellite markers was 27.5%.
LOH frequency in serum samples
Following PCR-based microsatellite analyses on blood serum
samples from 81 patients with a panel of six different polymor-
phic microsatellite markers, at least one LOH was found on
cell-free DNA in serum of 27 (33.5%) patients (Table 1). Three
patients displayed LOH at two markers in their blood (data not
shown). The overall LOH incidence of all analyzed microsatel-
lite markers in blood was 9.5%. Figure 2a depicts the LOH
distribution at the different microsatellite markers in the serum
samples of the 81 patients. Moreover, blood of the healthy
controls did not display LOH at any microsatellite marker used
(data not shown).
From 22 patients, both serum and tumor tissues were availa-
ble. Comparative analyses showed a lower LOH frequency in
serum than in tumor tissues (Figure 2b). The LOH distribution
of the corresponding serum and tumor samples was heteroge-
neous and only in three cases was LOH simultaneously
detected in both clinical materials, which were all derived from
patients with lobular breast cancer (data not shown).
Detection of DTC in bone marrow
DTC were detected in BM of 32 of 81 patients (39.5%). Four
of the five patients with metastatic disease at primary diagno-
sis were postmenopausal, hormone receptor positive and
DTC positive (Table 1). Recurrent disease was diagnosed in
15 of 81 patients (18.5%) after a median of 21 months (range
4 to 54 months), and 22 of 81 patients (27.0%) died after a
median of 4.3 years (range 2 months to 9 years). The occur-
rence of DTC in BM significantly correlated with distant metas-
tases (P < 0.05) but with no other clinicopathological factors
(Table 3). Both ER-positive and PR-positive patients more
often tended to have DTC in their BM than receptor-negative
patients (Table 1).
Clinical relevance of LOH frequency in serum
Statistical evaluations of the LOH frequency in blood from
breast cancer patients were performed with the following clin-
ical data: age, family history, tumor size, nodal status, histol-
ogy, grading, ER and PR status, CEA and CA15-3 (Table 1).
Table 3 summarizes the significant associations between
these parameters.
The occurrence of LOH at the entire marker set correlated
positively with the histologic type of carcinoma (P = 0.05) and
negatively with the histopathologic grading (P = 0.006, Tables
1 and 3). Most LOH were detected in blood of patients with
ductal breast cancer (38%) and a histopathologic grading of I
to II (45%, Table 1). Statistical evaluations of the LOH fre-
quency at the single markers showed that two markers
(D3S1255 and D9S171) were associated with clinicopatho-
logical parameters of the patients. The marker D9S171 was
only affected by LOH in patients with higher tumor stages of
pT2-4 (P < 0.05) and patients older than 55 years (P = 0.05,
Table 3).
In respect to the 76 patients with primary breast cancer with-
out overt metastases, LOH at both markers (D3S1255, P <
0.05 and D9S171, P < 0.02) significantly correlated with the
prevalence of recurrence (Table 3). As estimated by Kaplan-
Meier analysis, the median recurrence periods were 109 and
Figure 1
High DNA levels significantly associate with lobular breast cancer High DNA levels significantly associate with lobular breast cancer. The 
box plot shows the comparison of serum DNA concentrations (a) in 
patients with ductal (n = 60), lobular (n = 10) and other (n = 10) breast 
tumors, and (b) in patients with disseminated tumor cells (DTC)-nega-
tive and DTC-positive bone marrow (BM) status. *Statistical signifi-
cance according to the Mann and Whitney-U test for the non-
parametric comparison of two independent variables.Breast Cancer Research    Vol 11 No 5    Schwarzenbach et al.
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110 months (95% confidence interval (CI) 101 to 117 and
103 to 118) in patients who had no LOH at D3S1255 and
D9S171, respectively, whereas the periods were 69 and 43
months (95% CI 39 to 100 and 16 to 71) in patients who dis-
played LOH at D3S1255 (P = 0.009, Figure 3a) and D9S171
(P = 0.001, Figure 3b), respectively.
None of the LOH data correlated with a reduced overall sur-
vival rate. Whereas nodal status significantly correlated with
recurrence (P < 0.05) and overall survival (P < 0.001), histo-
logical grading was associated with a significant shorter over-
all survival (P < 0.03; data not shown).
Finally, we compared the occurrence of LOH at the particular
microsatellite markers in blood with the presence of DTC in
BM. However, our statistical assessments between LOH and
the BM status did not reach any statistical significance for the
marker analyzed (Table 3).
Discussion
In the current study we demonstrated a significant association
between cell-free tumor DNA in blood and relapse of breast
cancer patients after a follow-up time of 6 to 10 years. Further-
more, the detection of cell-free tumor DNA was not correlated
to the detection of DTC in BM as an established indicator of
MRD.
We detected markedly higher DNA levels in the blood of
patients with lobular breast carcinomas than in patients with
ductal tumors, whereas, inversely, the LOH incidence in blood
Table 3
Significant associations between the presence of DTC, serum DNA yields, LOH frequencies at the microsatellite markers and 
established risk factors determined by the Mann and Whitney-U test
Elevated
serum DNA
§LOH
complete
§LOH at D3S1255 §LOH at
D9S171 pos
$DTC
Age
< 55 years
> 55 years no no no P = 0.05 no
Tumor size
pT1
pT2-4 no no no P < 0.05 no
Nodal status
pN0
pN1-2 no no no no no
Metastasis
M0
M1 no no no no P < 0.05
Histology
Ductal
Lobular P < 0.03 P = 0.05 no no no
others
Grading
I-II
III no P = 0.006 no no no
$DTC
Positive P < 0.05 no no no
Negative
Recurrence no no P < 0.05
P = 0.009*
P < 0.02
P= 0.001
no
*Log rank test
§ loss of heterozygosity (LOH) detected in blood
$ disseminated tumor cells (DTC) detected in bone marrowAvailable online http://breast-cancer-research.com/content/11/5/R71
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of patients with ductal breast cancer was higher than in
patients with lobular cancer. These observations are not easy
to explain by an increased turn over of tumor cells because
controversial data on the apoptotic and LOH index of the dif-
ferent histological cancer types have been published [19-21].
Furthermore, according to the inadequate number of patients
with lobular cancer these data could also not be performed in
a multivariate analysis.
Concordant LOH profiles in autologous tumor tissues and
blood were only found in 3 of 22 patients where both types of
samples were available, whereas discordant LOH profiles
were seen in all other cases. This surprising finding may be
due to the known multifocal heterogeneity of breast carcino-
mas [22], the local necrosis of the areas of the primary tumor,
the potential contribution of tumor DNA derived from
micrometastatic cells to the pool of blood DNA [12] and the
masking of LOH caused by the dilution of tumor-derived DNA
by normal DNA [15,23].
Nevertheless, we discovered significant correlations between
the presence of LOH in blood and the clinical parameters of
our patients. The key finding was the association of LOH at the
microsatellite markers D3S1255 and D9S171 with the
relapse of the patients. In the literature there is little information
on the marker D3S1255 mapping to the chromosomal locus
3p24.2-25. However, it has been suggested for another tumor
entity that replication errors on 3p is an early event in tumor
development and that a tumor suppressor gene, which is
involved in the progression of esophageal squamous cell car-
cinoma, may exist near the 3p25 locus [24]. Moreover, the
well-known gene product CDKN2 (cyclin-dependent kinase
inhibitor) is located in the vicinity of the marker D9S171.
CDKN2 is a negative regulator of the cell cycle, and the loss
of this gene may, consequently, promote cell proliferation,
which may also explain its role in the pathogenesis of sporadic
breast cancer [25]. Besides the association of LOH at this
locus with the relapse of the breast cancer patients, we found
that the marker D9S171 was only affected by LOH in patients
with higher tumor stages of pT2-4, indicating additionally the
relationship between tumor load and the presence of such
DNA in serum.
Using a well-established antibody for the detection of DTC
[26], we found DTC in BM of nearly 40% of the patients, which
is comparable with other published studies demonstrating the
prognostic impact of DTC in the BM of primary breast cancer
patients [1,27-29]. In our study, the presence of DTC in BM
only correlated with distant metastases but with no other clin-
icopathologic data. Moreover, we found no relationship
between BM status and LOH on cell-free DNA in blood. This
finding suggests that the presence of DTC in BM of breast
cancer patients may not significantly contribute to the release
of DNA into blood.
In contrast to DTC, the half life of circulating tumor cells (CTC)
seems to be short (1 to 24 hours) and apoptotic cells signifi-
cantly contribute to the circulating tumor cell fraction in breast
cancer patients [30]. Genomic analyses at the single-cell level
have shown that DTC and CTC frequently display very hetero-
geneous tumor-specific aberrations, particular in patients with
early-stage cancer without overt metastases [31,32]. Further-
more, genomic and phenotypic differences between DTC,
CTC and the primary tumor have been documented in breast
cancer [33,34]. As a result, it has been suggested that tumor
cells disseminate in an early genomic state and that they
acquire genomic alterations after dissemination independent
form the primary tumor [35]. Thus, it can be speculated that
part of the DNA found in blood is derived from CTC which
could also explain the discrepancies in LOH patterns
observed between blood and autologous tumor tissues. We
did not perform CTC analysis in the current study because no
Figure 2
Distribution of the LOH incidences in blood and primary tumor Distribution of the LOH incidences in blood and primary tumor. Com-
parison of the loss of heterozygosity (LOH) frequencies detected at six 
different microsatellite markers (a) in blood serum samples from 81 
breast cancer patients, and (b) in serum and tumor samples from 22 
patients. The frequency of LOH was calculated by division of the 
number of LOH with the informative cases for each locus.Breast Cancer Research    Vol 11 No 5    Schwarzenbach et al.
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standardized method for CTC screening had been established
when samples were taken 6 to 10 years ago. Future genomic
analyses of CTC and DTC together with the assessment of
cell-free DNA will shed more light on the origin of cell-free
DNA in cancer patients.
Conclusions
The current study assessed the clinical relevance of LOH at
particular chromosomal regions on cell-free DNA circulating in
the peripheral blood of breast cancer patients, in particular in
the context of BM micrometastasis. The detection of LOH on
cell-free blood DNA was not related to the presence of DTC in
BM but showed a significant independent association to
breast cancer recurrence. The molecular analysis of cell-free
tumor DNA in blood may contribute to the identification of
breast cancer patients with an increased risk for relapse.
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